Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|April 24, 2014

Spectrum Pharmaceuticals Appoints New President and COO

Author(s)Melanie Sena

Spectrum Pharmaceuticals appoints Joseph Turgeon as president and COO.

Spectrum Pharmaceuticals, a biotechnology company with a primary focus in hematology and oncology, has appointed Joseph Turgeon, previously senior vice president and COO, as president and COO, replacing Ken Keller. Thomas Riga, previously vice president, corporate accounts, will become the senior vice president, COO.

Turgeon joined Spectrum in October 2012 and has over 30 years of pharmaceutical sales experience. Prior to joining the Spectrum, hespent 22 years at Amgen as VP of sales. Riga has over 15 years of pharmaceutical sales and management experience and has worked at Amgen, EliLilly, and Dendreon.


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.